- Priority Review granted based on positive results from two Phase 3 trials; if approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in more than a decade
- Regulatory submissions are also under review in China and Europe
- Dupixent is the leading biologic treatment for all five of its FDA-approved indications in new-to-brand prescriptions in the U.S.
Regeneron Pharmaceuticals And Sanofi Announce That Dupixent® sBLA Has Been Accepted For FDA Priority Review For Treatment of COPD With Type 2 Inflammation
Company Profile